Safety of Selective Intracoronary Hypothermia During Primary Percutaneous Coronary Intervention in Patients With Anterior STEMIDepartment of Cardiology, Essex Cardiothoracic Centre, Basildon, United Kingdom; Anglia Ruskin School of Medicine, Chelmford, Essex, United Kingdom.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Essex Cardiothoracic Centre, Basildon, United Kingdom; Anglia Ruskin School of Medicine, Chelmford, Essex, United Kingdom.
Department of Cardiology, Golden Jubilee National Hospital, Glasgow, United Kingdom.
Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Golden Jubilee National Hospital, Glasgow, United Kingdom; British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Show others and affiliations
2021 (English)In: JACC: Cardiovascular Interventions, ISSN 1936-8798, E-ISSN 1876-7605, Vol. 14, no 18, p. 2047-2055Article in journal (Refereed) Published
Abstract [en]
OBJECTIVES: The aim of this study was to determine the safety of selective intracoronary hypothermia during primary percutaneous coronary intervention (PPCI) in patients with anterior ST-segment elevation myocardial infarction (STEMI).
BACKGROUND: Selective intracoronary hypothermia is a novel treatment designed to reduce myocardial reperfusion injury and is currently being investigated in the ongoing randomized controlled EURO-ICE (European Intracoronary Cooling Evaluation in Patients With ST-Elevation Myocardial Infarction) trial (NCT03447834). Data on the safety of such a procedure during PPCI are still limited.
METHODS: The first 50 patients with anterior STEMI treated with selective intracoronary hypothermia during PPCI were included in this analysis and compared for safety with the first 50 patients randomized to the control group undergoing standard PPCI. In-hospital mortality, occurrence of rhythm or conduction disturbances, stent thrombosis, onset of heart failure during the procedure, and subsequent hospital admission were assessed.
RESULTS: In-hospital mortality was 0%. One patient in both groups developed cardiogenic shock. Atrial fibrillation occurred in 0 and 3 patients (P = 0.24), and ventricular fibrillation occurred in 5 and 3 patients (P = 0.72) in the intracoronary hypothermia group and control group, respectively. Stent thrombosis occurred in 2 patients in the intracoronary hypothermia group; 1 instance was intraprocedural, and the other occurred following interruption of dual-antiplatelet therapy consequent to an intracranial hemorrhage 6 days after enrollment. No stent thrombosis was observed in the control group (P = 0.50).
CONCLUSIONS: Selective intracoronary hypothermia during PPCI in patients with anterior STEMI can be implemented within the routine of PPCI and seems to be safe. The final safety results will be reported at the end of the trial.
Place, publisher, year, edition, pages
Elsevier, 2021. Vol. 14, no 18, p. 2047-2055
Keywords [en]
STEMI, infarct size, myocardial reperfusion injury, procedural safety, selective intracoronary hypothermia
National Category
Cardiology and Cardiovascular Disease
Identifiers
URN: urn:nbn:se:oru:diva-93952DOI: 10.1016/j.jcin.2021.06.009ISI: 000704941800017PubMedID: 34454860Scopus ID: 2-s2.0-85115767028OAI: oai:DiVA.org:oru-93952DiVA, id: diva2:1589292
Note
Funding agencies:
British Heart Foundation RE/18/6134217
Abbott Laboratories
Hexacath
2021-08-312021-08-312025-02-10Bibliographically approved